Literature DB >> 6333890

Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia.

R Foa, F Lauria, P Lusso, M C Giubellino, M T Fierro, M L Ferrando, D Raspadori, L Matera.   

Abstract

The phenotypic expression and functional capacity of natural killer (NK) T-lymphocytes (E+, OKT3+) were analysed in a series of untreated patients with B-cell chronic lymphocytic leukaemia (B-CLL). The mean value of NK activity of B-CLL T-lymphocytes, tested against the K562 cell line, was significantly depressed (P less than 0.01) in the 20 cases studied, compared with that of normal T-cells. Incubation with human leucocyte interferon produced an increase (P less than 0.05) in NK activity, although the mean value was still significantly lower (P less than 0.05) than that obtained with normal T-cells. Furthermore, the formation of effector-target conjugates was significantly lower (P less than 0.01) among B-CLL T-cells compared with normal T-lymphocytes. Despite the reduced NK functions observed in the majority of B-CLL patients, the capacity of T-cells to react with the monoclonal antibody (MoAb) Leu-7 (HNK-1 clone), assessed in 60 patients, was significantly higher (P less than 0.001) in B-CLL than in normal blood (mean 24% +/- 10.6 SD v 9% +/- 4.2), irrespective of the clinical stage of the disease. These findings suggest that the reduced cytotoxic ability of B-CLL T-lymphocytes may be due either to an expanded population of immature T-cells which already express a cytotoxic-like phenotype (E+, OKT3+, HNK-1+) but which lack adequate cytotoxic functions, or, alternatively, to an intrinsic defect of the natural effectors present within the T-cell population of B-CLL. The T-cell functional abnormalities documented in this study, together with other defective functions previously described, may be implicated in some of the complications frequently associated with B-CLL, particularly the high incidence of secondary neoplasms. There is growing evidence that natural cytotoxicity may play a major role in the immune surveillance system, both against tumour cells and virus-infected cells (Herberman & Ortaldo, 1981). Natural killer (NK) cells are a morphologically homogeneous population of large granular lymphocytes with azurophilic granules in the cytoplasm (Timonen et al, 1981), which are non-adherent and express receptors for the Fc portion of IgG. About 50% of these cells form rosettes with sheep red blood cells (E-rosettes) (West et al, 1977). A monoclonal antibody (MoAb) which appears to react with practically all human NK cells (HNK-1 clone, Leu-7; Becton Dickinson) has been recently produced (Abo & Balch, 1981).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6333890     DOI: 10.1111/j.1365-2141.1984.tb03998.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Cytotoxic lymphocytes in B-cell chronic lymphocytic leukemia. A flow cytometric study of peripheral blood, lymph nodes and bone marrow.

Authors:  L W Terstappen; B G de Grooth; I Segers-Nolten; J Greve
Journal:  Blut       Date:  1990-02

2.  Impaired mitogen responses of the non-leukaemic B cells from patients with chronic lymphocytic leukaemia.

Authors:  A Morgan; J Eaves; J W Mockford; V Malkovska
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

3.  Phenotypic and functional characterization of the circulating NK compartment in hairy cell leukaemia.

Authors:  R Foa; F Lauria; P Lusso; D Raspadori; M T Fierro; P L Tazzari; L Caudana; L Matera
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

4.  Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.

Authors:  L E Robertson; A W Denny; Y O Huh; W Plunkett; M J Keating; J A Nelson
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 5.  Immunological and genetic abnormalities in chronic lymphocytic leukaemia. Impact of the purine analogues.

Authors:  G Juliusson
Journal:  Drugs       Date:  1994       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.